Research is designed to investigate interactions between stromal/mesenchymal cells and ovarian surface epithelium (i.e., ovarian germinal epithelium) in normal and tumorigenic ovarian tissue. Over 90% of all ovarian cancers originate in the ovarian surface epithelium (OSE) that covers the surface of the ovary. An ovarian surface stromal cell population of mesenchymal origin underlie and provide structural support to the OSE. THE HYPOTHESIS TO BE TESTED IS THAT NORMAL AND TUMORIGENIC OVARIAN SURFACE EPITHELIUM IS REGULATED BY MESENCHYMAL-EPITHELIAL CELL INTERACTIONS MEDIATED BY THE LOCAL PRODUCTION AND ACTION OF GROWTH STIMULATORS AND GROWTH INHIBITORS. Abnormal cell growth associated with ovarian carcinogenesis is speculated to in part be the result of alterations in these normal cell-cell interactions. Preliminary observations indicate that ovarian stromal cell secretory products can regulate normal and tumorigenic OSE growth in vitro. A nude mouse model revealed that ovarian stromal cells also have a dramatic effect on ovarian tumor growth and progression in vivo. Ovarian tumors may be potentially subcategorized as stromally dependent for an inhibition versus stimulation of tumor growth and progression. The limited availability of normal human ovarian cell types requires an animal model to be utilized. Due to the similarity between bovine and human ovarian physiology and reproductive endocrinology, basic information will be obtained using a bovine ovarian model system. Normal and tumorigenic human tissue subsequently will be used to confirm and extend the basic hypothesis. The experimental approach consists of the following specific aims; 1) Investigate Bovine Ovarian Surface Epithelium (OSE) and Stromal/Mesenchymal Cell Function and Growth. 2) Investigate bovine OSE - Stromal Cell Interactions. 3) Investigate OSE - Stromal Interactions in normal and tumorigenic human tissue. The completion of these specific aims will provide a better understanding of cell-cell interactions between OSE and ovarian stromal cells in the control of OSE function and growth. Results will provide insight into the roles of specific mesenchymally derived growth factors in the regulation of normal and tumorigenic cell growth. The antagonistic actions of growth simulators and inhibitors provide an efficient mechanism to control the growth of OSE. It is anticipated that alterations in the cell-cell interactions identified will be an important factor in abnormal growth associated with carcinogenesis of the ovary. These observations will be essential for the future design of pharmacologic agents to detect, prevent and/or treat ovarian cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA064602-03
Application #
6269668
Study Section
Project Start
1998-02-01
Project End
1999-01-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Lu, Z; Yang, H; Sutton, M N et al. (2014) ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death Differ 21:1275-89
Cheng, Kwai Wa; Agarwal, Roshan; Mitra, Shreya et al. (2012) Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med 4:125-41
Badgwell, D B; Lu, Z; Le, K et al. (2012) The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene 31:68-79
Zou, Chun-Fang; Jia, Luoqi; Jin, Hongyan et al. (2011) Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer 11:22
Cheong, Jae-Ho; Park, Eun Sung; Liang, Jiyong et al. (2011) Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 10:2350-62
Agarwal, Roshan; Carey, Mark; Hennessy, Bryan et al. (2010) PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs 11:615-28
Ishida, Seiko; McCormick, Frank; Smith-McCune, Karen et al. (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17:574-83
Short, John D; Dere, Ruhee; Houston, Kevin D et al. (2010) AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 49:429-39
Liu, Shuying; Murph, Mandi; Panupinthu, Nattapon et al. (2009) ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8:3695-701
Huang, Shaoyi; Chang, In Soon; Lin, Wenbo et al. (2009) ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep 30:159-68

Showing the most recent 10 out of 117 publications